New framework aims to create personalized genetic therapies for rare neurodevelopmental disorders

McGill University researchers have developed and tested a new way to facilitate the creation of personalized genetic therapies for children with rare neurodevelopmental disorders.

Currently, many children suffering from rare disorders are left without a realistic path to treatment, given that the underlying genetic changes may affect only a handful of patients. As such, there is a need for platforms that treat diagnosis as the starting point for therapeutic evaluation rather than the endpoint of a diagnostic journey.

The study presents a framework for making such therapies more accessible. Published in the American Journal of Human Genetics, it demonstrates a process to bridge the gap between genetic diagnosis and treatment by presenting a roadmap that connects diagnosis to the screening of individualized therapies.

Collaboration with CHU Sainte-Justine

This approach leverages a diagnosis to guide the design of a genetic-based therapy, with the aim of providing a more direct path to treatment."

Julia Macintosh, lead author, PhD student in McGill's Department of Neurology and Neurosurgery

What makes the approach different is that it creates a single workflow that takes patients from genetic diagnosis through treatment development and testing.

"This is a wonderful example of researchers at McGill University and CHU Sainte-Justine working together to support families in Quebec. We hope this model can also be useful to genetic diagnostic centres around the world," said senior author Carl Ernst, Professor in McGill's Department of Psychiatry and head of the Interventional Genetics Unit at the Neuro. The research was supported in part by McGill's DNA to RNA program.

How the approach works

The process begins with a blood sample, which is used to create brain cells carrying the same genetic mutation as the patient. Scientists can then use those cells to study the disorder and test potential treatments in the laboratory.

To demonstrate the approach, the researchers used it to develop and test an experimental RNA therapy for a child with Kleefstra syndrome, a rare genetic disorder that can cause developmental delays, intellectual disability and difficulties with speech and communication. The experimental therapy was tested in cells in the laboratory. Further research is needed before it could be tested in humans.

Many of the technologies needed to develop personalized genetic therapies already exist, the authors note. The challenge now is integrating them into health-care systems so more patients can benefit.

Source:
Journal reference:

Macintosh, J., et al. (2026). Integrating clinical diagnostics with interventional genetics for neurodevelopmental disorders. The American Journal of Human Genetics. DOI: 10.1016/j.ajhg.2026.09.006. https://www.sciencedirect.com/science/article/pii/S0002929726003472

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CHLA researcher explores immune mechanisms behind rare pediatric neuroinflammatory diseases